The Impact of Migraine on Canadians' Productivity: A Real-World Pharmacy-Based Study
Study Details
Study Description
Brief Summary
This is a cross-sectional, real-world observational, community pharmacy-based study in which patients treated with triptans for their migraine will self-report productivity and activity impairment using a web-based portal or paper-based questionnaire.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The primary objective of this study is to estimate the productivity and activity impairment associated with migraine in adults treated with triptans in Canada.
Participant identification will be made using pharmacies member of the PROxy Network. Eligible participants will be identified using the prescription of any formulation of triptans either when filling or refilling a prescription of a triptan or in the pharmacy electronic database (patients with a renewal in the last 3 months).
The PROxy Network is a research network bringing together community pharmacies across Quebec to facilitate the generation of real-world evidence. This network is designed to better understand a disease or a treatment through data coming directly from patients using patient-reported outcomes (PROs). The PROxy Network is an initiative of PeriPharm Inc., a company specializing in pharmacoeconomics and outcomes research.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No group
|
Drug: observational study
No intervention, observational study
|
Outcome Measures
Primary Outcome Measures
- The Migraine Disability Assessment (MIDAS) questionnaire [Baseline]
Patient-reported outcome: The Migraine Disability Assessment (MIDAS) is a 5-item, self-administered questionnaire designed to quantify headache-related disability over the past 3 months. The MIDAS is scored as the sum of five questions, each measured as days in the last 3 months, and then categorized into four disability grades with higher scores indicating greater disability: ''Grade I - Little to no disability'' for 0 to 5 days, ''Grade II - Mild disability'' for 6 to 10 days, ''Grade III - Moderate disability'' for 11 to 20 days and ''Grade IV - Severe disability'' for 21 days and over.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years of age or older;
-
New or current prescription (renewal in the last 3 months) of any formulation of triptans medication (i.e., almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan and frovatriptan);
-
Working full or part-time or going to school full or part-time;
-
Ability to read and understand English or French;
-
Signature of informed consent form (ICF).
Exclusion Criteria:
-
Patients participating in a clinical trial.
-
Patients filling a one-time vacation/emergency prescription (i.e. without a complete pharmacy file).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | PROxy Network, an initiative of PeriPharm inc. | Montreal | Quebec | Canada | H2Y 2H4 |
Sponsors and Collaborators
- PeriPharm
Investigators
- Principal Investigator: Jean Lachaine, PeriParm inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PROxy202201